Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.
Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.
复制标题
DOI：
10.1007/s00259-013-2379-x
复制
发表时间：
2013-07
影响因子：
9.1
通讯作者：
Cheng, Leo L.
中科院分区：
文献类型：
--
作者：
Spur, Eva-Margarete;Decelle, Emily A.;Cheng, Leo L.
前列腺癌 (PCa) 的代谢组学成像旨在提高体内成像能力，以便可以非侵入性地定位 PCa 肿瘤，以指导活检并在前列腺切除术之前评估侵袭性，以及评估和监测新活检诊断的无症状 PCa 患者的 PCa 生长。代谢组学研究代谢物的整体变化，可以通过分析整个可测量的代谢组来评估恶性肿瘤状况，而不是仅关注某些代谢物或孤立的代谢途径。目前，PCa代谢组学的研究主要利用磁共振波谱（MRS）和质谱（MS）完成。通过 MRS 成像，从磁共振成像获得的解剖图像将与根据每个位置的 MRS 计算出的疾病状况特异性代谢组图谱值进行映射。例如，切除的整个前列腺的成像证明了代谢组学特征能够区分癌灶和组织学良性区域。此外，前列腺活检的 MS 代谢组学成像发现了可以区分 PCa 和良性组织的代谢组表达模式。代谢组学成像提供了识别癌症病变以指导前列腺活检并在体内或离体非侵入性评估 PCa 侵袭性的潜力，以提高病理学分析的能力。这种成像能力不仅可以用于前列腺癌，还可以应用于不同的组织和器官，以评估其他人类恶性肿瘤或代谢疾病。
Metabolomic imaging of prostate cancer (PCa) aims to improve in vivo imaging capability so that PCa tumors can be localized non-invasively to guide biopsy and evaluated for aggressiveness prior to prostatectomy, as well as to assess and monitor PCa growth for newly biopsy-diagnosed, asymptomatic PCa patients. Metabolomics studies global variations of metabolites with which malignancy conditions can be evaluated by profiling the entire measurable metabolome, instead of focusing only on certain metabolites or isolated metabolic pathways. At present, the study of PCa metabolomics is mainly accomplished utilizing magnetic resonance spectroscopy (MRS) and mass spectrometry (MS). With MRS imaging, the anatomic image, obtained from magnetic resonance imaging, is mapped with values of disease condition-specific metabolomic profiles calculated from MRS of each location. For example, imaging of removed whole prostates demonstrated the ability of metabolomic profiles to differentiate cancerous foci from histologically benign regions. Additionally, MS metabolomic imaging of prostate biopsies uncovered metabolomic expression patterns that could discriminate between PCa and benign tissue. Metabolomic imaging offers the potential to identify cancer lesions to guide prostate biopsy and evaluate PCa aggressiveness non-invasively in vivo, or ex vivo to increase the power of pathology analysis. Potentially, this imaging ability could be possible not only with PCa, but applied to different tissues and organs to evaluate other human malignancies or metabolic diseases.
登录
查看更多内容
影响因子：
3.7
作者：
Lodi A;Ronen SM
通讯作者：
Ronen SM
影响因子：
9.9
作者：
Godbolt, AK;Waldman, AD;Rossor, MN
通讯作者：
Rossor, MN
影响因子：
11.5
作者：
Cazares, Lisa H.;Troyer, Dean;Semmes, O. John
通讯作者：
Semmes, O. John
影响因子：
11.2
作者：
Cheng, LL;Burns, MA;Wu, CL
通讯作者：
Wu, CL
影响因子：
3.3
作者：
Burns, MA;Taylor, JL;Cheng, LL
通讯作者：
Cheng, LL